CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 834 enrolled
Drug / intervention
MEDI0382 low dose +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03235050
NCT03235050Phase 2Completed

A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus

AstraZeneca·interventional·Posted Aug 1, 2017·Updated Aug 17, 2020

In Brief

A Phase 2 clinical trial evaluating MEDI0382 low dose, MEDI0382 mid dose, and 3 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 834 participants across 119 sites in 8 countries.

Detailed Summary

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Canada, Czechia, Germany, Mexico, Russia, Slovakia, United States
CollaboratorsMedImmune LLC

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 1, 2017
Enrollment StartAug 2, 2017
Primary CompletionMay 3, 2018
Study CompletionJun 14, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.9 years ago

Interventions

MEDI0382 low dosedrug

Pharmaceutical form: solution Route of administration: subcutaneous

MEDI0382 mid dosedrug

Pharmaceutical form: solution Route of administration: subcutaneous

MEDI0382 high dosedrug

Pharmaceutical form: solution Route of administration: subcutaneous

Placebodrug

Pharmaceutical form: solution Route of administration: subcutaneous

Liraglutidedrug

Pharmaceutical form: solution Route of administration: subcutaneous